Cancer Family
Malignant Neoplasm
CI-CAN-00000025CAExplore in graph →
20,108 active trials259 approved drugs3,741 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000025CAExplore in graph →
Clinical trials
90,662 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (11,158)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06357598 | Preoperative Neoadjuvant Immunotherapy Combined With Chemotherapy for Stage Ⅲ Unresectable Non-small Cell Lung Cancer(PILOT) | unknown | Phase 4 | 30 | The Affiliated Hospital of Qingdao UniversityOTHER | 1 | Apr 10, 2024 | clinicaltrials |
| NCT04511533 | Dacomitinib for Treatment of Patients in India With Metastatic Non Small Cell Lung Cancer With EGFR Activating Mutations | completed | Phase 4 | 101 | PfizerINDUSTRY | 1 | Apr 5, 2024 |
| clinicaltrials |
| NCT03817853 | An Open-Label, Single Arm Study of Obinutuzumab Short Duration Infusion in Patients With Previously Untreated Advanced Follicular Lymphoma | completed | Phase 4 | 114 | Hoffmann-La RocheINDUSTRY | 7 | Apr 4, 2024 | clinicaltrials |
| NCT06049693 | Iron Prehabilitation in Endometrial Cancer(IROGYN) | completed | Phase 4 | 156 | National and Kapodistrian University of AthensOTHER | 1 | Mar 29, 2024 | clinicaltrials |
| NCT06316908 | Permanent Celiac Plexus Block: Comparison of Pain Score in Unilateral and Bilateral Posterior Percutaneous Approach | completed | Phase 4 | 30 | Sindh Institute of Urology and TransplantationOTHER | 1 | Mar 19, 2024 | clinicaltrials |
| NCT06311916 | Efficacy and Safety of Neoadjuvant Therapy in Patients With Resectable HCC Screened by a Multimodal Deep Learning Model. | not yet recruiting | Phase 4 | 312 | Chen XiaopingOTHER | 0 | Mar 15, 2024 | clinicaltrials |
| NCT06300099 | Dexamethasone Versus Dexmedetomidine as Adjuncts to Serratus Anterior Plane Block | unknown | Phase 4 | 126 | Al-Azhar UniversityOTHER | 0 | Mar 12, 2024 | clinicaltrials |
| NCT04904653 | The Effectiveness of Hemopatch® in the Reduction of Post-surgical Serous Drainage | unknown | Phase 4 | 118 | Instituto de Investigación Hospital Universitario La PazOTHER | 1 | Mar 6, 2024 | clinicaltrials |
| NCT05124002 | Recombinant Human Adenovirus Type 5 Plus HAIC of FOLFOX for Intrahepatic Cholangiocarcinoma | unknown | Phase 4 | 66 | Beijing Tsinghua Chang Gung HospitalOTHER | 1 | Mar 4, 2024 | clinicaltrials |
| NCT06031493 | A Multimodal Intervention Program to Improve Sexual Health and Self-perceived Quality of Life in Patients Treated for Cervical Cancer (PROVIDENCE)(PROVIDENCE) | unknown | Phase 4 | 122 | Hospital Clinic of BarcelonaOTHER | 1 | Feb 28, 2024 | clinicaltrials |
| NCT06041425 | The Effects of Oxycodone Versus Sufentanil on Pain and Inflammatory Response After TACE | completed | Phase 4 | 40 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Feb 28, 2024 | clinicaltrials |
| NCT06217185 | The Efficacy and Safety of Pyrotinib, Trastuzumab Combined With Taxanes in the Treatment of Trastuzumab-treated HER2+ Advanced Breast Cancer (ABC). | recruiting | Phase 4 | 100 | Hebei Medical University Fourth HospitalOTHER | 1 | Feb 28, 2024 | clinicaltrials |
| NCT06258486 | Ultrasound Guided Inguinal Indocyanine Green Injection to Identify and Pre-emptively Seal Lymphatic Leaks | unknown | Phase 4 | 100 | Kaiser PermanenteOTHER | 0 | Feb 26, 2024 | clinicaltrials |
| NCT06276933 | A Study of Camrelizumab Combined With Chemotherapy ± Thalidomide in First-line Treatment of Patients With Advanced Non-small Cell Lung Cancer (NSCLC) | not yet recruiting | Phase 4 | 104 | Tongji UniversityOTHER | 0 | Feb 26, 2024 | clinicaltrials |
| NCT06269445 | The Efficacy and Safety of Lcaritin Combined With Bevacizumab and FOLFIRI in Treatment of Liver Metastases From Colorectal Cancer | unknown | Phase 4 | 20 | Sir Run Run Shaw HospitalOTHER | 1 | Feb 21, 2024 | clinicaltrials |
| NCT01735955 | Study to Allow Access to Nilotinib for Patients Who Are on Nilotinib Treatment in a Novartis-sponsored Study | completed | Phase 4 | 57 | Novartis PharmaceuticalsINDUSTRY | 16 | Feb 8, 2024 | clinicaltrials |
| NCT06245824 | Trastuzumab Deruxtecan (T-DXd) With Pyrotinib in First-line HER2-positive Unresectable or Metastatic Breast Cancer Trial | not yet recruiting | Phase 4 | 51 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Feb 7, 2024 | clinicaltrials |
| NCT05803096 | Self-Administered Nitrous Oxide (SANO) During Transrectal Prostate Biopsy to Reduce Patient Anxiety and Pain | completed | Phase 4 | 143 | Beth Israel Deaconess Medical CenterOTHER | 1 | Jan 30, 2024 | clinicaltrials |
| NCT03432949 | Radium-223 Combined With Dexamethasone as First-line Therapy in Patients With M+CRPC(TRANCE) | unknown | Phase 4 | 24 | University Health Network, TorontoOTHER | 1 | Jan 24, 2024 | clinicaltrials |
| NCT06169410 | Ramucirumab Combined With Nab-paclitaxel, Lobaplatin, and S-1 in Neoadjuvant Transformation Therapy for Advanced Gastric Cancer | unknown | Phase 4 | 140 | Yang Jianjun, PhDOTHER | 1 | Jan 23, 2024 | clinicaltrials |
| NCT04180176 | Prospective Clinicogenomic Program(PCG) | completed | Phase 4 | 945 | Genentech, Inc.INDUSTRY | 1 | Jan 17, 2024 | clinicaltrials |
| NCT05075538 | COVID-19: Immune Response in Patients With Cancer Undergoing mRNA Vaccination Against SARS-CoV-2(I-SPARC) | terminated | Phase 4 | 152 | Jules Bordet InstituteOTHER | 1 | Jan 17, 2024 | clinicaltrials |
| NCT03858166 | Efficacy and Safety of PEG-rhG-CSF Secondary Prophylaxis vs. Therapeutic Administration in Patients With Ovarian Cancer | terminated | Phase 4 | 68 | Shandong UniversityOTHER | 1 | Jan 5, 2024 | clinicaltrials |
| NCT06144099 | Prothrombin Complex Concentrate vs Fresh Frozen Plasma in Goal-directed Bleeding Management in Non-cardiac Surgery | unknown | Phase 4 | 154 | Konkuk University Medical CenterOTHER | 0 | Jan 2, 2024 | clinicaltrials |
| NCT04401059 | Synergistic Effect of Elemene Plus TKIs Compared With TKIs in EGFR-mutated Advanced NSCLC：Prospective Study(SELECT-2) | unknown | Phase 4 | 744 | Tian XieOTHER | 1 | Dec 27, 2023 | clinicaltrials |
| NCT01088750 | Surgery Alone or With CYC VBL and PRED or CVP Alone in Stage IA or IIA Nodular Lymphocyte-Predominant Hodgkin Lymphoma(EuroNetLP1) | completed | Phase 4 | 225 | Christine Mauz-KörholzOTHER | 1 | Dec 13, 2023 | clinicaltrials |
| NCT03700411 | Influence of Opioid Analgesia on Circulating Tumor Cells in Open Colorectal Cancer Surgery(POACC-1) | completed | Phase 4 | 125 | The Institute of Molecular and Translational Medicine, Czech RepublicOTHER | 1 | Dec 7, 2023 | clinicaltrials |
| NCT03700541 | Influence of Opioid Analgesia on Circulating Tumor Cells in Laparoscopic Colorectal Cancer Surgery(POACC-2) | completed | Phase 4 | 71 | The Institute of Molecular and Translational Medicine, Czech RepublicOTHER | 1 | Dec 7, 2023 | clinicaltrials |
| NCT01856023 | HD IL-2 + Ipilimumab in Patients With Metastatic Melanoma(PROCLIVITY02) | terminated | Phase 4 | 29 | Clinigen, Inc.INDUSTRY | 1 | Dec 5, 2023 | clinicaltrials |
| NCT01416077 | Decreasing Postoperative Complications by Goal-Directed Fluid Therapy During Esophageal Resection | completed | Phase 4 | 64 | University Hospital, LinkoepingOTHER | 1 | Dec 4, 2023 | clinicaltrials |
| NCT05949424 | OPTI - DOSE: Optimal Dosing of Oral Anticancer Drugs in Older Adults(OPTI-DOSE) | unknown | Phase 4 | 30 | University Medical Center GroningenOTHER | 1 | Nov 29, 2023 | clinicaltrials |
| NCT03677596 | A Study Of Two Inotuzumab Ozogamicin Doses in Relapsed/ Refractory Acute Lymphoblastic Leukemia Transplant Eligible Patients | completed | Phase 4 | 102 | PfizerINDUSTRY | 8 | Nov 22, 2023 | clinicaltrials |
| NCT04297254 | A Study to Assess the Safety and Efficacy of Lenvatinib as First-line Treatment in Participants With Unresectable HCC | completed | Phase 4 | 50 | Eisai Pharmaceuticals India Pvt. LtdINDUSTRY | 1 | Nov 15, 2023 | clinicaltrials |
| NCT06118762 | Clinical Study of Fruquintinib Combined With Raltitrexed in the Treatment of Metastatic Colorectal Cancer | recruiting | Phase 4 | 30 | The First Affiliated Hospital of Nanchang UniversityOTHER | 1 | Nov 7, 2023 | clinicaltrials |
| NCT04569799 | Accuracy of Contrast-Enhanced Ultrasound for Hepatocellular Carcinoma Post TACE(TACE) | completed | Phase 4 | 26 | Milton S. Hershey Medical CenterOTHER | 1 | Nov 2, 2023 | clinicaltrials |
| NCT06115174 | Clinical Study Evaluating the Anticancer Effect of Pentoxiphylline in Patients With Metastatic Colorectal Cancer(CRC - PTX) | unknown | Phase 4 | 44 | Tanta UniversityOTHER | 0 | Nov 2, 2023 | clinicaltrials |
| NCT03824808 | Effect of Perioperative Intravenous Lidocaine Infusion in Robotic-Assisted Urologic Surgery | terminated | Phase 4 | 21 | University of Missouri-ColumbiaOTHER | 1 | Oct 25, 2023 | clinicaltrials |
| NCT00180739 | Safety Trial of Magnetic Resonance (MR) Guided Focused Ultrasound Surgery (FUS) in Women With Uterine Fibroids Wishing to Pursue Pregnancy in the Future | withdrawn | Phase 4 | 0 | Imperial College LondonOTHER | 1 | Oct 24, 2023 | clinicaltrials |
| NCT06003673 | A Clinical Study of Tislelizumab Combined With TACE and Lenvatinib in the Neoadjuvant Treatment of Resectable HCC | unknown | Phase 4 | 20 | First Affiliated Hospital of Fujian Medical UniversityOTHER | 1 | Oct 24, 2023 | clinicaltrials |
| NCT04625517 | Performance of Contrast-Enhanced Spectral Mammography to Assess Neoadjuvant Chemotherapy Response (CEDM) | terminated | Phase 4 | 6 | University of Texas Southwestern Medical CenterOTHER | 1 | Oct 12, 2023 | clinicaltrials |
| NCT05071703 | Evaluation of TRILACICLIB in Chinese Patients With Extensive-stage Small Cell Lung Cancer (ES-SCLC) for Chemotherapy-induced Myelosuppression, Antitumor Effects of Combination Regimens, and Safety in a Real-world Study | completed | Phase 4 | 30 | Jiangsu Simcere Pharmaceutical Co., Ltd.INDUSTRY | 1 | Oct 6, 2023 | clinicaltrials |
| NCT04790045 | Lymph Node Microenvironment Modifications in Patients With CLL Treated With Venetoclax-based Regimens(LymBIO) | not yet recruiting | Phase 4 | 30 | Paolo GhiaOTHER | 0 | Oct 3, 2023 | clinicaltrials |
| NCT00923702 | Trial of Two Versus Three Doses of Human Papillomavirus (HPV) Vaccine in India | unknown | Phase 4 | 22,729 | Partha BasuOTHER | 1 | Sep 28, 2023 | clinicaltrials |
| NCT05926336 | The Effects of Using Different Anesthetics on the Prognosis of Primary Tumors and Its Mechanism of Action | unknown | Phase 4 | 1,316 | Kaohsiung Medical University Chung-Ho Memorial HospitalOTHER | 1 | Sep 28, 2023 | clinicaltrials |
| NCT03469271 | Maintain Respiratory Muscle Function and Reduce Pneumonia Risk in Cancer Patients | completed | Phase 4 | 63 | Mayo ClinicOTHER | 1 | Sep 26, 2023 | clinicaltrials |
| NCT05860907 | Clinical Study of Huaier Granules in Patients With Advanced Breast Cancer Without Visceral Metastasis | not yet recruiting | Phase 4 | 384 | Fudan UniversityOTHER | 1 | Sep 26, 2023 | clinicaltrials |
| NCT06055543 | Impact of a New Plant-based High-energy Oral Nutritional Supplement on Nutritional Outcomes in Malnourished Patients | unknown | Phase 4 | 140 | Danone Specialized NutritionINDUSTRY | 1 | Sep 26, 2023 | clinicaltrials |
| NCT06047535 | Naxitamab and Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF) Combined With Isotretinoin for Maintenance Treatment of Patients With High-Risk Neuroblastoma in First Complete Response. | not yet recruiting | Phase 4 | 62 | SciClone PharmaceuticalsINDUSTRY | 0 | Sep 21, 2023 | clinicaltrials |
Data updated 23 days agoSource updated Apr 10, 2024source: clinicaltrials